A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 1, 2008

Conditions
Glioma
Interventions
DRUG

RTA 744

Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.

DRUG

RTA 744 injection

Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.

Trial Locations (4)

75246

Baylor University Medical Center: Neuro-Oncology Associates, Dallas

75309

University of Texas Southwestern Medical Center, Dallas

77030

The University of Texas M. D. Anderson Cancer Center, Houston

90095

UCLA School of Medicine, Department of Neurology, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY